Objective. To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi).
INTRODUCTION
Axial spondyloarthritis (SpA) is a chronic inflammatory disease that is estimated to affect 0.9-1.4% of adults in the US and encompasses both nonradiographic axial SpA and radiographic axial SpA (1, 2) . Radiographic axial SpA is also referred to as ankylosing spondylitis (AS). The disease is typically characterized by inflammatory back pain and radiographically defined sacroiliac (SI) joint structural damage (2, 3) . Patients with axial SpA may also exhibit peripheral musculoskeletal (inflammatory arthritis, enthesitis, and dactylitis) and extraarticular (uveitis, psoriasis, and inflammatory bowel disease [IBD] ) involvement.
Currently, the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network, the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism, and the National Institute for Health and Care Excellence guidelines for the management of axial SpA recommend treatment with tumor necrosis factor inhibitors (TNFi) in patients with axial SpA who do not respond or tolerate nonsteroidal antiinflammatory drugs (NSAIDs) (4) (5) (6) . Approximately 30-40% of patients with AS do not achieve adequate disease control or symptom relief according to clinical trials of TNFi (7) (8) (9) (10) (11) (12) . In addition, some patients may not be eligible to receive TNFi due to relative contraindications (13) .
The interleukin-17 (IL-17) axis has been linked to the immunopathology of axial SpA (14, 15) . IL-17 inhibition has demonstrated efficacy in patients with AS; however, an IL-17 antagonist has not been evaluated in a population that exclusively consisted of patients with prior inadequate response to or intolerance of TNFi in a clinical trial setting (16) . This is an important population on which to focus, given that it has been shown to be difficult to treat, with treatment responses lower in magnitude than observed in biologics-naive populations (17, 18) .
Ixekizumab is a high-affinity monoclonal antibody that selectively targets IL-17A (19) . Here we present the 16-week results of COAST-W, a phase III clinical trial investigating the efficacy and safety of ixekizumab in patients with active radiographic axial SpA and previous inadequate response to or intolerance of 1 or 2 TNFi.
PATIENTS AND METHODS
Trial design. COAST-W is a multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group, outpatient clinical trial of 1 year's duration, followed by an optional 2-year extension trial (COAST-Y) (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40753/abstract). Patient enrollment and data collection occurred at 106 sites located in 15 countries across North America, South America, Europe, and Asia (for a list of investigators and sites, see Supplementary Appendix A, available at http://onlinelibrary.wiley.com/doi/10.1002/art.40753/ abstract). This trial was conducted in accordance with the ethical principles of the Declaration of Helsinki and in compliance with local laws and regulations. All participants provided informed consent. COAST-W protocol and consent forms were approved by each site's institutional review board or ethics committee. The trial was registered with ClinicalTrials.gov (NCT02696798) and the European Union Clinical Trials Register (2015-003937-84).
Trial participants. Complete inclusion and exclusion criteria are provided in Supplementary Appendix B (available at http://onlinelibrary.wiley.com/doi/10.1002/art.40753/abstract). Eligible subjects were age ≥18 years, required to have an established diagnosis of axial SpA and fulfillment of ASAS classification criteria for radiographic axial SpA (i.e., radiographic evidence of sacroiliitis according to the modified New York criteria and having ≥1 SpA feature), and required to have a history of back pain for ≥3 months with an age at onset of <45 years (20) (21) (22) . SI joint radiographs were scored by central readers. All patients fulfilling ASAS criteria for radiographic axial SpA (20) also fulfilled the modified New York criteria for AS (21) .
Additional inclusion criteria included a baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (23) of ≥4, a baseline total back pain numeric rating scale score of ≥4, and a history of therapy for axial SpA of at least 12 weeks' duration prior to screening. Patients were required to have discontinued at least 1 TNFi, but no more than 2 TNFi, either due to intolerance or due to an inadequate response (in the opinion of the investigator) to treatment with a single TNFi for at least 12 weeks at an adequate dose. The required TNFi washout periods are described in Supplementary Appendix B and were based upon the half-lives of the respective TNFi.
The exclusion criteria included total spinal ankylosis (according to the site investigator's opinion), active or recent infections, current or history of lymphoproliferative or malignant disease (<5 years prior to baseline) or other medical conditions (e.g., systemic inflammatory diseases or chronic pain conditions such as fibromyalgia), other non-TNF biologic or other immunomodulatory agent treatments, or surgical procedures that could pose an unacceptable risk to patients or that could confound interpretation of trial results. Patients with IBD (Crohn's disease or ulcerative colitis) were eligible if no disease | 601 exacerbations had occurred for ≥6 months (stable treatment allowed). Patients with anterior uveitis were eligible if no exacerbations had occurred for ≥4 weeks.
Patients could continue to receive the following medications at a stable dose: sulfasalazine (≤3 gm/day), methotrexate (≤25 mg/week), prednisone or equivalent (≤10 mg/day), and NSAIDs. No changes to these medications were allowed during the blinded treatment dosing period, except for safety reasons. Analgesics were also allowed according to the eligibility criteria (see Supplementary Appendix B, available at http://onlinelibrary.wiley.com/ doi/10.1002/art.40753/abstract).
Randomization and blinding.
Patients were randomly assigned (1:1:1) to receive subcutaneous administration of ixekizumab 80 mg every 2 weeks (IXEQ2W group), ixekizumab 80 mg every 4 weeks (IXEQ4W group), or matched placebo from week 0 to week 16. Patients randomized to the ixekizumab treatment regimens were randomized (1:1) to receive either an 80-mg or 160-mg starting dose of ixekizumab at week 0. The 2 starting doses were included in order to assess the impact of starting dose on week 16 responses, following regulatory agency feedback. All patients received the same frequency and number of injections regardless of treatment arm or assigned starting dose.
During the double-blinded treatment period (weeks 0-16), site personnel, patients, and the sponsor trial team were blinded with regard to treatment. Randomization to treatment groups was determined using a computer-generated, randomsequence, interactive web-response system with follow-up confirmation by site personnel using the confirmation number present on the investigational product packaging. Randomization of treatment assignment (including starting dose) was stratified by country, high-sensitivity C-reactive protein (CRP) level (≤5 or >5 mg/liter) at screening, and the number of prior TNFi taken (1 or 2) to achieve between-group comparability.
At week 16, patients entered the extended treatment period (weeks . Patients who were initially assigned to the placebo arm were, for the extended treatment period, randomly reassigned at week 16 to IXEQ4W or IXEQ2W with a 160-mg starting dose. Patients already receiving ixekizumab remained on their assigned treatment regimens through week 52.
Procedures of product administration. The investigational product was supplied in prefilled manual syringes for subcutaneous administration, with trial-specific labels. Ixekizumab and its matching placebo were visually indistinguishable from each other. To maintain blinding, all patients received 2 injections at week 0 and 1 injection every 2 weeks. Placebo patients received a placebo injection every 2 weeks and IXEQ4W patients received a placebo injection every other 2 weeks to maintain blinding. Patients assigned to an ixekizumab treatment regimen received their starting dose (either 80-mg ixekizumab [ Safety outcomes were assessed at every visit. Data on terms related to cerebrocardiovascular events and suspected IBD were adjudicated by external clinical event committees. Details on adjudication criteria are provided in Supplementary Appendix C.
Statistical analysis. The sample size of COAST-W was estimated to have 96% power for testing the superiority of IXEQ2W to placebo for an ASAS40 response at week 16 (for details on power analysis assumptions, see Supplementary Appendix C).
Efficacy analyses for the blinded treatment dosing period included all randomized patients according to the treatment to which they were assigned. Analyses of the IXEQ2W and IXEQ4W treatment groups were performed without regard to the starting dose. Missing values (including for those patients who discontinued trial treatment) were imputed as nonresponders using nonresponder imputation for categorical variables; continuous variables were analyzed using a mixed-effects model of repeated measures (MMRM) without imputation for missing values.
The primary analysis method for categorical outcome variables was logistic regression with treatment, geographic region, baseline CRP status (≤5 versus >5 mg/liter), and the number of prior TNFi taken included in the model. Secondary analysis of categorical outcomes was performed using Fisher's exact test when the logistic model did not converge due to sparse data.
The primary analysis method for continuous outcomes, except SPARCC MRI index scores, was MMRM with treatment, geographic region, baseline CRP level, the number of prior TNFi taken, baseline value, visit, baseline value-by-visit, and treatmentby-visit interaction as fixed factors. The primary analysis method for SPARCC MRI index scores was analysis of covariance (ANCOVA) with observed case analysis, with inclusion only of patients with both baseline (between 42 days prior to and 14 days after the first injection) and week 16 (injection date at week 16 [±14 days]) SPARCC MRI index scores. The ANCOVA included treatment, geographic region, baseline CRP level, number of prior TNFi taken, and baseline value.
A graphical multiple testing strategy was implemented for primary and major secondary objectives to control the overall familywise Type I error rate at a 2-sided alpha level of 0.05 (see Supplementary Figures 2-4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40753/ abstract). There was no adjustment for multiple comparisons for any other analyses. The analyses investigating efficacy prior to week 16 were not included in the multiple testing strategy.
Descriptive analyses (with no prespecified hypothesis testing) were performed using the safety population, which was defined as all randomized patients who received ≥1 dose of the trial drug, according to assigned treatments. Safety data were summarized as the frequency of events occurring in each treatment group during the blinded treatment dosing period.
RESULTS

Patient disposition and baseline characteristics.
The Consolidated Standards of Reporting Trials (CONSORT) diagram is provided in Figure 1 . Of the 610 patients assessed for trial eligibility, 316 were randomly assigned to either placebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n =114), and 294 patients were designated as ineligible at screening or were discontinued prior to randomization. The predominant reason for ineligibility at screening was the lack of definitive sacroiliitis according to centrally read SI joint radiographs (n = 217 [35 Clinical end points. Ixekizumab was found to be superior to placebo for the primary and all major secondary end points at week 16 with both ixekizumab treatment regimens, except for ASAS-HI scores with IXEQ2W ( Figures 2-4 and Supplementary Table 5, available Statistically significant improvements in measures of disease activity were observed among patients treated with IXEQ2W or IXEQ4W relative to placebo at week 16, as measured by a change from baseline in ASDAS and BASDAI scores, as well as achieve- Figure 2 . Proportion of patients achieving A, 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society criteria (ASAS40) or B, ASAS20 responses through week 16 when treated with placebo (PBO), ixekizumab every 2 weeks (IXEQ2W), or ixekizumab every 4 weeks (IXEQ4W). * = P < 0.05; † = P < 0.01; ‡ = P < 0.001, all versus placebo by logistic regression analysis, except for week 1 with ASAS40, for which Fisher's exact test was used due to model nonconvergence. Only analyses at week 16 were included in the prespecified multiple testing strategy. n = number of patients in the analysis category; N = number of patients in the analysis population.
| 605 ment of ASDAS <2.1 (inactive or low disease activity) ( Figures 3A-C) . Patient function was also significantly improved at week 16 in patients treated with IXEQ2W or IXEQ4W relative to placebo, as mea sured by a change from baseline in BASFI scores ( Figure 3D ).
Quality of life end points. Statistically significant improvements in quality of life, as measured by mean change from baseline in the SF-36 PCS, were reported at week 16 for patients treated with IXEQ2W and IXEQ4W versus placebo ( Figure 3E) . Similarly, statistically significant improvements in health functioning, as measured by mean change from baseline in ASAS-HI scores, were reported at week 16 among patients treated with IXEQ4W versus placebo ( Figure 3F ).
Spinal MRI and systemic inflammation.
Spinal MRI and systemic inflammation significantly improved in patients treated with IXEQ2W or IXEQ4W, as demonstrated by the mean change from baseline in SPARCC MRI index spine scores and in mean change from serum baseline CRP levels, respectively, at week 16 versus placebo ( Figures 4A and B) .
Safety. Safety outcomes reported in COAST-W during the blinded treatment dosing period are summarized in Table 2 . Overall mean ± SD exposure was 109.1 ± 19.6 days or a total of 94.4 patient-years. The proportions of patients in each ixekizumab treatment regimen who reported treatment-emergent adverse events (TEAEs) were higher than those for placebo patients and were similar between ixekizumab treatment regimens. Most reported TEAEs were mild or moderate in severity. Severe TEAEs occurred in 7 placebo patients (6.7%), 4 IXEQ2W patients (4.1%), and 4 IXEQ4W patients (3.5%). The most frequently reported TEAEs (occurring in ≥5% of patients receiving ixekizumab overall) were upper respiratory tract infections and injection site reactions. AEs leading to discontinuation were reported for 2 placebo patients (1.9%), 3 IXEQ2W patients (3.1%), and 10 IXEQ4W patients (8.8%) (for specific AEs, see Supplementary Table 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40753/abstract). Few serious AEs were reported, with similar rates across treatment arms: n = 5 (4.8%) for placebo patients, n = 3 (3.1%) for IXEQ2W patients, and n = 4 (3.5%) for IXEQ4W patients. One death (suicide) occurred in the IXEQ2W treatment arm, in a patient with a documented prior history of depression of ~1 year (reported as mild at study entry), and was judged by the blinded principal investigator to be unrelated to the investigational product.
The incidence of infections was higher for ixekizumab than for placebo, with most infections being mild or moderate (Table 2) . Two Candida infections were reported in the IXEQ2W study arm (1 esophageal and 1 genital candidiasis), 1 herpes zoster infection was reported in the IXEQ4W study arm, and no infections were reported in the placebo group. Serious infections were reported in 2 patients in the IXEQ4W group (1 peritonitis and 1 pharyngitis; both patients continued the trial). No new cases of tuberculosis or reactivation were reported during the trial.
Reported injection site reactions were all mild or moderate in severity, occurred across all treatment arms (n = 6 [5.8%] for placebo, n = 16 [16.3%] for IXEQ2W, and n = 9 [7.9%] for IXEQ4W), and led to treatment discontinuation in only 2 patients (1 each in the IXEQ2W and IXEQ4W groups).
Mild neutropenia (grade 1) occurred more frequently in the ixekizumab arms than in the placebo arm, was transient in nature, and resolved spontaneously while ixekizumab treatment continued. A single case of grade 2 neutropenia was reported in each ixekizumab treatment arm; 1 of these cases existed before treatment began. One malignancy (acute promyelocytic leukemia [PML]) was reported 4 weeks postbaseline in the IXEQ4W treatment arm. The single report of grade 4 neutropenia was in this same patient. A post hoc analysis of a serum sample collected prior to investigational product exposure revealed that this patient had a genetic risk factor for acute PML (PML/retinoic acid receptor ɑ mutation) prior to trial entry. Treatment was discontinued in this patient. 
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Single adjudicated cerebrocardiovascular events were reported in the placebo and IXEQ2W treatment arms. The cerebrocardiovascular events were confirmed as stent placement (placebo group) and atrial fibrillation (IXEQ2W group), respectively. Both of these patients continued treatment through week 16 . No major adverse cerebrocardiovascular events were reported dur- † Common TEAEs are defined as those that occurred at a frequency of ≥5% for patients receiving ixekizumab (both treatment regimen populations combined). ‡ Injection site reaction high-level terms include injection site, pain, erythema, dermatitis, hypersensitivity, pruritus, bruising, rash, and paresthesia or reaction (unspecified). § Confirmed cerebrocardiovascular events only. ¶ Anterior uveitis was not a prespecified AE of special interest but was included in the prespecified analyses.
ing the blinded treatment dosing period. Depression was reported more often in patients taking placebo (n = 5 [4.8%]) than in patients taking IXEQ2W (n = 2 [2.0%]) and IXEQ4W (n = 0). IBD was reported in 1 patient (1.0%) in the placebo arm (colitis), no patients in the IXEQ2W arm, and in 3 patients (2.6%) in the IXEQ4W arm (1 colitis, 1 ulcerative colitis, and 1 Crohn's disease). Two cases (1 in the placebo group and 1 in the IXEQ4W group) were flares in patients with a preexisting diagnosis of IBD. Of the other 2 IBD cases (IXEQ4W group), 1 case was in a current smoker (smoking since 1994) with a perianal cyst reported in 2010 and accompanying intermittent abdominal pain since that time. The other case was in a long-term smoker (since 2009), who stopped smoking 3 months prior to trial entry, with a prior history of anemia (2012-2014) and intermittent diarrhea since 2011 (ongoing but mild at time of trial entry). All reported cases of IBD were adjudicated as "probable." Anterior uveitis was reported in 3 IXEQ2W patients (3.1%) and 2 IXEQ4W patients (1.8%); 3 of these 5 patients (2 in the IXEQ2W group and 1 in the IXEQ4W group) were documented to have a preexisting history of anterior uveitis; 4 of the 5 patients were HLA-B27 positive, and all had longstanding disease (experiencing symptoms for at least 7 years and up to 28 years). Psoriasis was reported in 2 patients with a previous medical history of psoriasis (1 in the placebo group and 1 in the IXEQ4W group).
Treatment-emergent antidrug antibodies were observed in 3 placebo patients (2.9%), 4 IXEQ2W patients (4.1%), and 8 IXEQ4W patients (7.1%). Most of the reported antidrug antibodies were classified as being low titer, 2 IXEQ2W patients (2.0%) and 1 IXEQ4W patient (0.9%) were reported as having moderate titers, and 1 IXEQ2W patient (0.9%) was reported with high titers. Neutralizing antidrug antibodies were detected in 3 IXEQ4W patients (2.7%). No associations were identified between treatment-emergent antidrug antibody status and ASAS40 response, injection site reactions, or potential allergic/ hypersensitivity events with either ixekizumab treatment regimen.
DISCUSSION
The COAST-W trial is the first large, randomized, controlled trial focusing exclusively on radiographic axial SpA patients with prior treatment failure (inadequate response to or intolerance of 1 or 2 TNFi). In that respect, this study differs from other reported phase III studies of radiographic axial SpA that enrolled exclusively or predominantly biologic DMARD (bDMARD)-naive patients. Ixekizumab was superior to placebo in reducing the signs and symptoms of radiographic axial SpA in this population of patients with longstanding disease and very high disease activity. For the primary end point (ASAS40 response), both IXEQ2W and IXEQ4W were superior to placebo at week 16. Statistically significant and clinically meaningful improvements over placebo were also observed at week 16 for all major secondary end points, including measures of disease activity, function, and quality of life for IXEQ4W and for all but 1 (ASAS-HI) major secondary end points for IXEQ2W. Statistically significant improvements over placebo were reported early in the trial for all of these end points. In addition, and despite baseline levels of spinal inflammation being relatively low, thereby hampering the ability to show improvement, a statistically significant and objective effect on spinal inflammation was observed for IXEQ2W and IXEQ4W, as measured by the SPARCC MRI index score, which was supported by parallel improvements in CRP levels. The spinal MRI data are the first to be reported in a large subset of patients with prior intolerance of or inadequate response to TNFi in the context of a placebo-controlled registration study.
Despite the greater exposure with the IXEQ2W regimen, IXEQ2W did not show a clinically meaningful incremental increase in observed efficacy relative to the IXEQ4W regimen. Similarly, the week 0 starting dose of ixekizumab 160 mg did not reveal a clinically meaningful incremental improvement in week 16 response rates relative to the 80-mg starting dose for either ixekizumab regimen. The impact of starting dose on speed of onset requires further analysis.
Ixekizumab showed an acceptable safety profile in this patient population with longstanding and very active disease. The frequency of TEAEs in this population (patients with prior inadequate response to or intolerance of TNFi) was higher across all treatment arms, including placebo, than those reported in a bDMARD-naive population with radiographic axial SpA from another phase III ixekizumab study (COAST-V, NCT02696785) (30) . TEAEs occurred more often with ixekizumab than with placebo, mostly driven by upper respiratory tract infections and injection site reactions. Serious AEs occurred at similar rates across ixekizumab and placebo treatment arms. The reported frequencies for total TEAEs and serious AEs are consistent with those reported among patients with psoriasis and psoriatic arthritis (PsA) treated with ixekizumab (31) (32) (33) (34) . Discontinuations due to AEs were similar for IXEQ2W relative to placebo but higher for IXEQ4W relative to placebo, with no particular AE driving the difference. The explanation for this discrepancy is unclear, given that there were no discontinuations due to AEs in the IXEQ4W treatment arm in the study of ixekizumab treatment in bDMARDnaive patients with radiographic axial SpA (30) .
Infection frequencies were higher in patients treated with ixekizumab relative to placebo. The majority of infections were mild, with the most commonly reported being upper respiratory tract infections and nasopharyngitis. Serious infections were uncommon (n = 2). Reported infection frequencies were higher than those reported in COAST-V, but consistent with or lower than those reported in trials of ixekizumab for PsA and psoriasis (30) .
Injection site reactions (high-level terms) were higher in patients treated with ixekizumab relative to placebo, and similar to or lower than previously observed in trials of ixekizumab for PsA and psoriasis (33, 34) . One case of grade 4 neutropenia was reported in the IXEQ4W treatment arm in a patient with treatment-| 609 emergent acute PML who had a genetic risk factor for this disease. In the IXEQ2W treatment arm, one patient with a documented prior history of depression committed suicide, which was judged by the blinded investigator to be unrelated to the investigational product.
The incidences of IBD and acute anterior uveitis in the current study involving patients with prior inadequate response to or intolerance of 1 or 2 TNFi, and longstanding (mean ± SD symptom duration 18.4 ± 11.1 years) and very active disease, were higher than reported among bDMARD-naive patients with radiographic axial SpA treated with ixekizumab (30) . Certain comorbidities in axial SpA, especially IBD and acute anterior uveitis, have been reported to be associated with longer disease duration (35) . Integrated data from the ixekizumab axial SpA studies, as well as longer-term data, are needed to better understand whether the IBD events observed in the current study reflect the recruited patient population, study treatment, other factors (such as discontinuation of prior TNFi), or a combination of the above (36) .
The incidence of ixekizumab antidrug antibodies was low and consistent with previous reports in patients with PsA and prior inadequate response to or intolerance of 1 or 2 TNFi (34). Ixekizumab antidrug antibodies were not associated with immune reactions or reductions in efficacy.
TNFi and 1 IL-17A antagonist (secukinumab) are the only approved biologic agents for treatment of AS. The ixekizumab results reported here for patients with inadequate response to or intolerance of 1 or 2 TNFi are consistent with those previously reported for secukinumab in patients with inadequate response to or intolerance of 1 TNFi (subset of 85 patients from the MEA SURE-2 study) (18) . However, given that other baseline characteristics may also differ between these 2 studies, direct comparisons should not be made between the trial results. Both MEASURE-2 and COAST-W demonstrate that IL-17A antagonists are efficacious and well-tolerated in patients with prior intolerance of or inadequate response to TNFi.
The COAST-W trial has several strengths. It is the first large, randomized, controlled trial to focus exclusively on patients with radiographic axial SpA with a prior inadequate response to or intolerance of 1 or 2 TNFi. This focus allowed for a comprehensive evaluation of the baseline characteristics, burden of disease, and treatment efficacy and safety in this population. COAST-W also used the ASAS40 response as the primary end point, reflecting major improvement and representing a more stringent end point than the commonly used ASAS20. In addition, COAST-W is the first placebo-controlled trial to generate spinal MRI data in a TNFiintolerant or inadequate responder population. Conversely, the current data set is limited to a 16-week treatment period. Longerterm data, which are being collected through 1 year of treatment in the present trial, as well as during an optional 2-year extension trial, will provide further information on the long-term efficacy and safety of ixekizumab.
In conclusion, the findings of this study demonstrate that the ixekizumab treatment regimens yield rapid and significant improvements in the signs and symptoms of radiographic axial SpA, as well as a significant reduction in inflammation of the spine as measured by MRI, when compared to placebo. The current results support ixekizumab as a treatment option for patients with radiographic axial SpA and prior inadequate response to or intolerance of TNFi.
